BTC Capital Management Inc. Sells 165 Shares of Danaher Co. (NYSE:DHR)

BTC Capital Management Inc. reduced its stake in shares of Danaher Co. (NYSE:DHR) by 0.6% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 25,935 shares of the conglomerate’s stock after selling 165 shares during the period. BTC Capital Management Inc.’s holdings in Danaher were worth $5,953,000 as of its most recent filing with the SEC.

Several other large investors have also bought and sold shares of the stock. Decker Retirement Planning Inc. purchased a new position in shares of Danaher in the fourth quarter worth about $31,000. Teachers Insurance & Annuity Association of America bought a new stake in Danaher during the third quarter worth about $39,000. MidAtlantic Capital Management Inc. purchased a new stake in shares of Danaher in the 3rd quarter valued at $40,000. FSA Wealth Management LLC bought a new position in Danaher during the 3rd quarter worth approximately $50,000. Finally, Darwin Wealth Management LLC purchased a new position in shares of Danaher in the third quarter valued at about $55,000. 79.05% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on DHR. Stifel Nicolaus upped their target price on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research report on Wednesday, October 23rd. Stephens reiterated an “overweight” rating and issued a $315.00 price target on shares of Danaher in a research report on Wednesday, October 23rd. Scotiabank began coverage on Danaher in a report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price objective on the stock. Jefferies Financial Group dropped their target price on Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Wells Fargo & Company dropped their price objective on Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a research report on Thursday. Six analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $278.00.

Danaher Stock Down 0.3 %

NYSE:DHR opened at $223.16 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. Danaher Co. has a one year low of $221.34 and a one year high of $281.70. The stock has a 50-day simple moving average of $235.66 and a 200 day simple moving average of $253.24. The company has a market capitalization of $161.19 billion, a price-to-earnings ratio of 42.27, a price-to-earnings-growth ratio of 4.22 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.72%. During the same period in the prior year, the company earned $2.09 earnings per share. Sell-side analysts predict that Danaher Co. will post 8.15 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be paid a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.48%. Danaher’s dividend payout ratio is presently 20.45%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.